Reference
Coronas R, et al. Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Current Drug Safety 7: 92-98, No. 2, Apr 2012. Available from: URL: http://www.benthamscience.com/cds/ - Spain
Rights and permissions
About this article
Cite this article
Antipsychotics. Reactions Weekly 1441, 7 (2013). https://doi.org/10.1007/s40278-013-1617-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-013-1617-0